Source: European Medicines Agency (EU) Revision Year: 2018 Publisher: Merck Sharp & Dohme B.V., Waarderweg 39, 2031 BN Haarlem, The Netherlands
EMEND 125 mg hard capsules.
EMEND 80 mg hard capsules.
| Pharmaceutical Form |
|---|
|
Hard capsule. The 125 mg capsule is opaque with a white body and pink cap with “462” and “125 mg” printed radially in black ink on the body. The 80 mg capsules are opaque with a white body and cap with “461” and “80 mg” printed radially in black ink on the body. |
Each 125 mg capsule contains 125 mg of aprepitant. Each 80 mg capsule contains 80 mg of aprepitant.
Excipient with known effect: Each capsule contains 125 mg of sucrose (in the 125 mg capsule).
Excipient with known effect: Each capsule contains 80 mg of sucrose (in the 80 mg capsule).
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Aprepitant |
Aprepitant is a selective high-affinity antagonist at human substance P neurokinin 1 (NK1) receptors. |
| List of Excipients |
|---|
|
Capsule content: Sucrose Capsule shell (125 mg): Gelatin Capsule shell (80 mg): Gelatin Printing ink: Shellac |
Different pack sizes including different strengths are available.
Aluminium blister containing one 80 mg capsule.
Aluminium blister containing two 80 mg capsules.
5 Aluminium blisters each containing one 80 mg capsule.
Aluminium blister containing one 125 mg capsule.
5 Aluminium blisters each containing one 125 mg capsule.
Aluminium blister containing one 125 mg capsule and two 80 mg capsules.
Not all pack sizes may be marketed.
Merck Sharp & Dohme B.V., Waarderweg 39, 2031 BN Haarlem, The Netherlands
EU/1/03/262/001
EU/1/03/262/002
EU/1/03/262/003
EU/1/03/262/004
EU/1/03/262/005
EU/1/03/262/006
Date of first authorisation: 11 November 2003
Date of latest renewal: 22 September 2008
| Drug | Countries | |
|---|---|---|
| EMEND | Austria, Brazil, Canada, Cyprus, Germany, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Japan, Lithuania, Mexico, Netherlands, New Zealand, Poland, Romania, Singapore, Tunisia, Turkey, United Kingdom, United States, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
